copy and paste this google map to your website or blog!
Press copy button and paste into your blog or website.
(Please switch to 'HTML' mode when posting into your blog. Examples: WordPress Example, Blogger Example)
Input Form:Deal with this potential dealer,buyer,seller,supplier,manufacturer,exporter,importer
(Any information to deal,buy, sell, quote for products or service)
Omeros Corporation - FDA Approves Omeros’ YARTEMLEA® – First and Only . . . SEATTLE -- (BUSINESS WIRE)--Dec 24, 2025-- Omeros Corporation (NASDAQ: OMER) today announced that the U S Food and Drug Administration (FDA) has approved YARTEMLEA ® (narsoplimab-wuug) for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA), an often-fatal complication of stem-cell
Omeros Gets FDA Approval of Yartemlea - MarketWatch By Colin Kellaher Omeros has won U S Food and Drug Administration approval of its Yartemlea treatment for an often-fatal complication of stem-cell transplants
Omeros wins FDA nod for transplant therapy - MSN Omeros Corporation (OMER) announced on Wednesday that the U S FDA approved its lead asset, narsoplimab-wuug, as a treatment for hematopoietic stem cell transplant-associated thrombotic
FDA Approval of Omeros’ YARTEMLEA Establishes New Standard of Care. . . Omeros secures FDA approval for YARTEMLEA, the first and only therapy for hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA) The approval is backed by high complete response and survival rates, with a favorable safety profile for both adults and children, marking a significant advancement in the treatment of this often-fatal transplant complication
FDA Approves Omeros Yartemlea, First Approved Drug For Rare Post . . . Omeros Corp (OMER) said Thursday that the U S Food and Drug Administration has approved Yartemlea (narsoplimab-wuug) for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA), a rare and often fatal complication following stem cell transplantation
FDA Approves Omeros’ YARTEMLEA® – First and Only Therapy Indicated for . . . Omeros Corporation (NASDAQ: OMER) today announced that the U S Food and Drug Administration (FDA) has approved YARTEMLEA ® (narsoplimab-wuug) for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA), an often-fatal complication of stem-cell transplantation driven by activation of the lectin
US FDA approves Omeros drug to treat dangerous transplant complication . . . The drug, branded Yartemlea, is used to treat a condition known as transplant-associated thrombotic microangiopathy (TA-TMA), a serious complication that can develop after stem cell transplants, particularly those that use healthy cells from a donor